⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628205 | 0.81 | TSHR (0.61) | — | |
| Hydrochloric Acid SCHEMBL5151093 | 0.78 | TSHR (0.58) | — | |
| SCHEMBL28136801 | 0.75 | — | — | |
| SCHEMBL7440484 | 0.75 | — | — | |
| SCHEMBL10413245 | 0.75 | MAPT (0.33) | — | |
| SCHEMBL2642572 | 0.75 | MAPT (0.47) | — | |
| SCHEMBL7738343 | 0.75 | TDP1 (0.54) | — | |
| SCHEMBL31231921 | 0.74 | MAPT (0.62) | — | |
| SCHEMBL4188927 | 0.73 | ALDH1A1 (0.68) | — | |
| SCHEMBL8926778 | 0.73 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE37781-E1 | VIRICIDES, PROTEASE INHIBITOR | DUPONT PHARMACEUTICALS COMPANY | 2002-07-02 | — | — | US | claimed |
| US-5811422-A | USEFUL FOR TREATING VIRAL INFECTIONS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-22 | — | — | US | claimed |
| EP-0815108-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
| US-5683999-A | Cyclic urea HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-04 | — | — | US | claimed |
| EP-0607334-B1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | DU PONT MERCK PHARMA (US) | 1997-07-30 | — | — | EP | claimed |
| US-5616578-A | Method of treating human immunodeficiency virus infection using a cyclic protease inhibitor in combination with a reverse transcriptase inhibitor | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-04-01 | — | — | US | claimed |
| US-5610294-A | VIRAL TREATMENT | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-11 | — | — | US | claimed |
| WO-1996029329-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-26 | — | — | WO | claimed |
| US-5559110-A | HIV ANTIVIRAL, GOOD SYSTEMIC ABSORPTION ADMINISTERED BY MOUTH | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-24 | — | — | US | claimed |
| US-5543517-A | VIRICIDES | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-08-06 | — | — | US | claimed |
| EP-0607334-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS. | DU PONT MERCK PHARMA (US) | 1994-07-27 | — | — | EP | claimed |
| WO-1993007128-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-15 | — | — | WO | claimed |
| CN-103936716-A | Diamide compounds having muscarinic receptor antagonist and beta 2 adrenoceptor agonist activity | THERAVANCE INC | 2014-07-23 | — | — | CN | disclosed |
| CN-102405218-B | Muscarinic receptor antagonists and beta2Diamide compounds having adrenergic receptor agonist activity | THERAVANCE INC | 2014-06-04 | — | — | CN | disclosed |
| CN-102405218-A | Muscarinic receptor antagonists and beta2Diamide compounds having adrenergic receptor agonist activity | THERAVANCE INC | 2012-04-04 | — | — | CN | disclosed |
| CN-1942472-B | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORP. (KR) | 2012-02-15 | — | — | CN | disclosed |
| EP-0239129-B1 | HYDROQUINOLINE COMPOUNDS, COMPOSITIONS CONTAINING SAME AND PROCESSES FOR PREPARING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-25 | — | — | EP | disclosed |
| EP-0435503-A1 | Improvements in or relating to gylcopeptide derivatives | ELI LILLY AND COMPANY (US) | 1991-07-03 | — | — | EP | disclosed |
| US-4963566-A | ANTIULCER AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-16 | — | — | US | disclosed |
| EP-0239129-A2 | Hydroquinoline compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-30 | — | — | EP | disclosed |